What are the best routes to market in DTx?

Beyond clinical evidence, the right commercialization model is key to drive adoption of DTx. A number of DTx companies have chosen pharma partnerships as their route to market, but is pharma the safest and most efficient commercialization model for DTx companies? Employer and payer partnerships have proven to be better options for some companies and D2C can also be a valuable approach, especially for new players that aim to gain traction faster and easily collect RWD to improve the product. Perhaps routes to market undergo iterations as the product gains traction. An unexplored potential path is via medtech companies that are also seeking new ways to reach their customers. In this meeting we will have an informal chat about the understanding of the different routes to market and how they determine the success of a DTx product.